Serum Institute of India (SII) CEO Adar Poonawalla on Friday said that SII has this week started manufacturing 1st batch of Covovax, a Covid-19 immunization created by Novavax Inc.
“Excited to witness the first batch of Covovax being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing.” Adar Poonawalla said in a tweet.
Novavax will be the fourth Covid-19 immunization to go through a clinical trial for kids in India.
Hyderabad-based Bharat Biotech has effectively begun clinical preliminaries of Covaxin for youngsters 12 to 18 years old. A sum of 525 kids are essential for these preliminaries being led at the All India Institute of Medical Sciences (AIIMS) in New Delhi and Patna.
Inputs: India Today